Accordingly, Iwasa and colleagues demonstrated that the proteasome inhibitor Bortezomib (Bor) (Table 1) reduces the adhesion of B-ALL cells to MSCs by upregulating the expression of SPARC in BM-MSCs. The gene discussed is SPARC; the disease is acute lymphoblastic leukemia.